|Agilent Technologies Inc., of Santa Clara, Calif.||PD-L1 IHC 22C3 Pharmdx||Companion diagnostic; runs on the Dako Omnis platform||Identifies patients with non-small-cell lung cancer who are appropriate for first-line monotherapy with Keytruda (pembrolizumab)||Received approval from the U.S. FDA|
|Baxter International Inc., of Deerfield, Ill.||Oxiris||Filter set||To treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels||Received emergency use authorization from the U.S. FDA|
|Biocomposites Ltd., of Keele, U.K.||Stimulan||Calcium matrix||For use in infection management in bone and soft tissue||Received CE mark approval for mixing with the antibiotics vancomycin, gentamicin and tobramycin|
|Cagent Vascular LLC, of Wayne, Pa.||Serranator||Percutaneous transluminal angioplasty serration balloon catheter||For treating below-the-knee lesions in patients with peripheral artery disease||Received 510(k) clearance from the U.S. FDA|
|Mevion Medical Systems, of Littleton, Mass.||Mevion S250i||Proton therapy system with Hyperscan pencil beam scanning||For use in radiation treatment for cancer patients||Received a medical device license from Health Canada|
For more information about individual companies and/or products, see Cortellis.